GlycoBac announces partnership with MilliporeSigma
GlycoBac has partnered with MilliporeSigma to facilitate the distribution of our Sf-RVN cell line for commercial vaccine and gene therapy vector production. In addition to distributing Sf-RVN cells through a cGMP cell bank, MilliporeSigma will offer a chemically defined medium formulation specially designed for Sf-RVN cells. See the announcement from MilliporeSigma
|
GlycoBac has been featured in several media reports:
(University of Wyoming, April 1 2014)
(Wyoming business report, October 18, 2012)
(Casper star Tribune, April 22 2012)
UW Professor’s Company, UW Sign Agreement to Commercialize Research
(University of Wyoming, February 22 2012)
(Wyo Business Council, Dec 2011)
| 